BioNano Genomics Inc vs Core and Main Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Core and Main Inc trades at $46.18 (market cap $8.73B). The key difference: Core and Main Inc is far larger — about 639.1× BioNano Genomics Inc's market cap, and Core and Main Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | CNM | |
|---|---|---|
Market Cap | $13.66M | $8.73B |
Sector | Health | Technology |
52-Week High | $4.92 | $66.98 |
52-Week Low | $1.06 | $42.37 |
Enterprise Value | $16.26M | $11.02B |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Core & Main (CNM) trades at $45.9, down 0.86% today, with a bullish technical signal despite near-term pressure. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.57 beating expectations of $0.534. Revenue reached $7.44B in 2025 with 5.87% net margin, while analyst consensus remains positive with 57% buy ratings. Recent news highlights institutional activity including California State Teachers Retirement System increasing its position by 22.3% in Q1 2026.
CNM presents a compelling investment case with robust profitability (23.73% ROE) and improving cash flow trends, though elevated debt levels and competitive pressures warrant caution. The stock's current valuation at 19.76 P/E appears reasonable given growth prospects, with technical support at $46 providing downside protection. Upside potential exists if the company maintains its earnings beat streak and executes on FY26 guidance of $7.8-7.9B revenue.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →